328 results on '"Dutta, Aloke K."'
Search Results
2. Bivalent dopamine agonists with co-operative binding and functional activities at dopamine D2 receptors, modulate aggregation and toxicity of alpha synuclein protein
3. Analytical approximation of surface potential and analysis of C–V characteristics of bulk MOSFETs at cryogenic temperatures
4. Dopamine agonists in treatment of Parkinson's disease: an overview
5. Contributors
6. D-685 Reverses Motor Deficits and Reduces Accumulation of Human α-Synuclein Protein in Two Different Parkinson’s Disease Animal Models
7. Analytical models for the 2DEG concentration and gate leakage current in AlGaN/GaN HEMTs
8. A unified analytical drain current model for Double-Gate Junctionless Field-Effect Transistors including short channel effects
9. Targeting alpha synuclein and amyloid beta by a multifunctional, brain-penetrant dopamine D2/D3 agonist D-520: Potential therapeutic application in Parkinson’s disease with dementia
10. Novel multifunctional dopamine D2/D3 receptors agonists with potential neuroprotection and anti-alpha synuclein protein aggregation properties
11. A Theoretical Study of Negative Capacitance Field‐Effect Transistors (NCFETs) Using Ferroelectrics Having 1 st ‐ and 2 nd ‐Order Phase Transitions
12. Improved Surface Potential Based Compact Model for Bulk MOSFETs at Cryogenic Temperatures
13. Corrigendum to “D-578, an orally active triple monoamine reuptake inhibitor, displays antidepressant and anti-PTSD like effects in rats” [Eur. J. Pharmacol. 862 (2019) 172632]
14. An Empirical Model for Bulk Electron Mobility in Si at Cryogenic Temperatures
15. D‐512, a novel dopamine D2/3 receptor agonist, demonstrates greater anti‐Parkinsonian efficacy than ropinirole in Parkinsonian rats
16. A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses α-syn- and MPTP-induced toxicities in vivo
17. A Theoretical Study of Negative Capacitance Field‐Effect Transistors Using Ferroelectrics Having First‐ and Second‐Order Phase Transitions.
18. Efficacy of Hybrid Tetrahydrobenzo[d]thiazole Based Aryl Piperazines D-264 and D-301 at D2 and D3 Receptors
19. Assessment of Protective Role of Multifunctional Dopamine Agonist D-512 Against Oxidative Stress Produced by Depletion of Glutathione in PC12 Cells: Implication in Neuroprotective Therapy for Parkinson’s Disease
20. A New Charge-Based Analytical Model for the Gate Current in GaN HEMTs
21. A New Surface Potential-Based Analytical Model for MFIS NCFETs
22. Modification of agonist binding moiety in hybrid derivative 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-ol/-2-amino versions: Impact on functional activity and selectivity for dopamine D2/D3 receptors
23. Modeling of the Gate Tunneling Current in MFIS NCFETs
24. An improved asymmetric synthetic route to a novel triple uptake inhibitor antidepressant (2 S,4 R,5 R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2 H-pyran-4-ol (D-142)
25. Synthesis and characterization of brain penetrant prodrug of neuroprotective D-264: Potential therapeutic application in the treatment of Parkinson’s disease
26. Analytical one-dimensional current-voltage model for FD SOI MOSFETs including the effect of substrate depletion
27. The selective dopamine uptake inhibitor, D-84, suppresses cocaine self-administration, but does not occasion cocaine-like levels of generalization
28. Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: Effect on affinity and selectivity for dopamine D3 receptor
29. The high-affinity D2/D3 agonist D512 protects PC12 cells from 6-OHDA-induced apoptotic cell death and rescues dopaminergic neurons in the MPTP mouse model of Parkinsonʼs disease
30. Interaction of D3 preferring agonist (−)-N 6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)ethyl)-N 6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264) with cloned human D2L, D2S, and D3 receptors: potent stimulation of mitogen-activated protein kinases and G protein-coupled inward rectifier potassium channels
31. Approach Towards Development of Multifunctional Drugs As an Effective Strategy for Treatment of Parkinson’s Disease
32. Novel Potent Dopamine–Norepinephrine and Triple Reuptake Uptake Inhibitors Based on Asymmetric Pyran Template and Their Molecular Interactions with Monoamine Transporters
33. Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an exocyclic hydroxyl group: Interaction with dopamine, serotonin, and norepinephrine transporters
34. D-161, a novel pyran-based triple monoamine transporter blocker: Behavioral pharmacological evidence for antidepressant-like action
35. Three-dimensional quantitative structure-activity relationship (3D QSAR) and pharmacophore elucidation of tetrahydropyran derivatives as serotonin and norepinephrine transporter inhibitors
36. An analytical gate tunneling current model for MOSFETs having ultrathin gate oxides
37. An accurate, analytical, and technology-mapped definition of the surface potential at threshold and a new postulate for the threshold voltage of MOSFETs
38. An explicit surface-potential-based MOSFET model incorporating the quantum mechanical effects
39. Design, synthesis, and preliminary SAR study of 3- and 6-side-chain-extended tetrahydro-pyran analogues of cis- and trans-(6-benzhydryl-tetrahydropyran-3-yl)-benzylamine
40. The novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents
41. Interaction of novel hybrid compounds with the D3 dopamine receptor: Site-directed mutagenesis and homology modeling studies
42. D-578, an orally active triple monoamine reuptake inhibitor, displays antidepressant and anti-PTSD like effects in rats
43. A new approach to RF small-signal modeling of MOSFETs
44. Bivalent phenethylamines as novel dopamine transporter inhibitors: evidence for multiple substrate-binding sites in a single transporter
45. Interaction of cocaine-, benztropine-, and GBR12909-like compounds with wild-type and mutant human dopamine transporters: molecular features that differentially determine antagonist-binding properties
46. Structural requirements for 2,4- and 3,6-disubstituted pyran biomimetics of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine compounds to interact with monoamine transporters
47. Study of interface stresses in heterostructures using infrared piezobirefringence
48. Synthesis and biological characterization of novel hybrid 7-{[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors
49. Interaction between a hydroxypiperidine analogue of 4-(2-benzhydryloxy-ethyl)-1-(4-fluorobenzyl)piperidine and Aspartate 68 in the human dopamine transporter
50. Dopamine transporter as target for drug development of cocaine dependence medications
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.